<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788501</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCP_001</org_study_id>
    <nct_id>NCT01788501</nct_id>
  </id_info>
  <brief_title>Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease</brief_title>
  <official_title>Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare efficacy and safety of tacrolimus/methotrexate with
      cyclosporine/methotrexate for graft versus host disease prophylaxis in paediatric allogeneic
      hematopoietic stem cell transplantation patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of grade II-IV acute graft versus host disease</measure>
    <time_frame>day 100 post transplantation</time_frame>
    <description>Overall grade I graft-versus-host disease denoted stage 1 to 2 skin involvement with no liver or gut involvement. Overall grade II graft-versus-host disease denoted stage 3 skin involvement or stage 1 liver or gut involvement. Overall grade III graft-versus-host disease denoted stage 4 skin involvement or stage 2 to 4 liver or gut involvement without graft-versus-host disease as a major contributing cause of death. And Overall grade IV graft-versus-host disease denoted stage 4 skin involvement or stage 2 to 4 liver or gut involvement with graft-versus-host disease as a major contributing cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of infection</measure>
    <time_frame>day 100 post transplantation</time_frame>
    <description>Fever would be categorized as fever occured before engraftment and after engraftment. If microbiologically documented, pathogen would be specified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse drug reactions</measure>
    <time_frame>day 100 post transplantation</time_frame>
    <description>adverse drug reactions would be measured by Common Terminology Criteria for Adverse Events v3. And for determinating the likelihood of whether an adverse drug reaction is actually due to the drug, Naranjo algorithm would be used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)
Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine/Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)</description>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)</description>
    <arm_group_label>Cyclosporine/Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push</description>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <arm_group_label>Cyclosporine/Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hematological malignancy

          -  Age under 18 years old

          -  Serum bilirubin less than 1.5 X upper limit of normal

          -  Aspartate transaminase, Alanine transaminase less than 2.5 X upper limit of normal

          -  Alkaline phosphatase less than 2.5 X upper limit of normal

          -  Serum creatinine less than 1.5 X upper limit of normal

          -  Agrees to participate, and informed consent signed

        Exclusion Criteria:

          -  Evidence of HIV infection

          -  Documented uncontrolled disease (infections)

          -  Prior transplantation (hematopoietic stem cell or solid organs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JungMi Oh, Pharm.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyoung Jin Kang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

